Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

Thumbnail Image
Download
Name

Young_Discovery and.pdf

Size

2.86 MB

Format

Adobe PDF

Checksum (MD5)

dac98989b6a089d0ef4cef569926d39c

Author(s)
Chapuy, Bjoern
•
McKeown, Michael R.
•
Lin, Charles Y.
•
Monti, Stefano
•
Roemer, Margaretha G.M.
•
Qi, Jun
•
Rahl, Peter B.
•
Sun, Heather H.
•
Yeda, Kelly T.
•
Doench, John G.
more
Date Issued
December 2013
Journal
Cancer Cell
Publisher
Elsevier
Citation
Chapuy, Bjoern, Michael R. McKeown, Charles Y. Lin, Stefano Monti, Margaretha G.M. Roemer, Jun Qi, Peter B. Rahl, Heather H. Sun, Kelly T. Yeda, John G. Doench, Elaine Reichert, Andrew L. Kung, Scott J. Rodig, Richard A. Young, Margaret A. Shipp, and James E. Bradner. "Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma." Cancer Cell 24:6 (December 2013), pp. 777-790.
Version
Author's final manuscript
Abstract
Diffuse large B cell lymphoma (DLBCL) is a biologically heterogeneous and clinically aggressive disease. Here, we explore the role of bromodomain and extra-terminal domain (BET) proteins in DLBCL, using integrative chemical genetics and functional epigenomics. We observe highly asymmetric loading of bromodomain 4 (BRD4) at enhancers, with approximately 33% of all BRD4 localizing to enhancers at 1.6% of occupied genes. These super-enhancers prove particularly sensitive to bromodomain inhibition, explaining the selective effect of BET inhibitors on oncogenic and lineage-specific transcriptional circuits. Functional study of genes marked by super-enhancers identifies DLBCLs dependent on OCA-B and suggests a strategy for discovering unrecognized cancer dependencies. Translational studies performed on a comprehensive panel of DLBCLs establish a therapeutic rationale for evaluating BET inhibitors in this disease.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Whitehead Institute for Biomedical Research
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
http://creativecommons.org/licenses/by-nc-nd/4.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/103897
DOI of Published Version
https://doi.org/10.1016/j.ccr.2013.11.003
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.